These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15200356)

  • 1. Bronchodilator reversibility testing: laboratory practices in Australia and New Zealand.
    Borg BM; Reid DW; Walters EH; Johns DP
    Med J Aust; 2004 Jun; 180(12):610-3. PubMed ID: 15200356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantial variation exists in spirometry interpretation practices for airflow obstruction in accredited lung function laboratories across Australia and New Zealand.
    Holt NR; Thompson BR; Miller B; Borg BM
    Intern Med J; 2019 Jan; 49(1):41-47. PubMed ID: 30043534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing bronchodilator reversibility: agreed standards are urgently needed.
    Jenkins C; Young I
    Med J Aust; 2004 Jun; 180(12):605-6. PubMed ID: 15200354
    [No Abstract]   [Full Text] [Related]  

  • 4. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease.
    Reid DW; Soltani A; Johns DP; Bish R; Williams TJ; Burns GP; Walters EH
    Intern Med J; 2003 Dec; 33(12):572-7. PubMed ID: 14656230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.
    Yang IA; Brown JL; George J; Jenkins S; McDonald CF; McDonald VM; Phillips K; Smith BJ; Zwar NA; Dabscheck E
    Med J Aust; 2017 Nov; 207(10):436-442. PubMed ID: 29129177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization of lung function testing: current practices in laboratories in Australia and New Zealand.
    Hall GL; Gain KR
    Respirology; 2006 Jul; 11(4):511-2. PubMed ID: 16771928
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose Response to Transnasal Pulmonary Administration of Bronchodilator Aerosols via Nasal High-Flow Therapy in Adults with Stable Chronic Obstructive Pulmonary Disease and Asthma.
    Li J; Zhao M; Hadeer M; Luo J; Fink JB
    Respiration; 2019; 98(5):401-409. PubMed ID: 31473748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining the optimal time to assess the reversibility of airway obstruction.
    El Ghoul J; Abouda M; Triki M; Ghourabi A; Charfi R
    Lung India; 2019; 36(2):123-130. PubMed ID: 30829246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors determining performance of bronchodilator reversibility tests in middle-aged and elderly.
    Lehmann S; Vollset SE; Nygaard HA; Gulsvik A
    Respir Med; 2004 Nov; 98(11):1071-9. PubMed ID: 15526807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection.
    D'Vaz N; Okitika TA; Shackleton C; Devadason SG; Hall GL
    Pediatr Pulmonol; 2019 May; 54(5):531-536. PubMed ID: 30719873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative functional criteria to assess airflow-limitation reversibility in asthma.
    Tavares e Castro A; Matos P; Tavares B; Matos MJ; Segorbe-Luís A
    Rev Port Pneumol (2006); 2015; 21(2):69-75. PubMed ID: 25926369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice.
    Griffiths C; Feder G; Wedzicha J; Foster G; Livingstone A; Marlowe GS
    Respir Med; 1999 Dec; 93(12):903-8. PubMed ID: 10653053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference values for spirometry and their use in test interpretation: A Position Statement from the Australian and New Zealand Society of Respiratory Science.
    Brazzale D; Hall G; Swanney MP
    Respirology; 2016 Oct; 21(7):1201-9. PubMed ID: 27457870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma.
    Bussamra MH; Cukier A; Stelmach R; Rodrigues JC
    Chest; 2005 Feb; 127(2):530-5. PubMed ID: 15705992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.
    Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M
    Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of patients with chronic obstructive pulmonary disease in the primary care setting: focus on the role of spirometry and bronchodilator reversibility.
    Stoloff SW
    J Fam Pract; 2011 Apr; 60(4 Suppl Diagnosis):S9-16. PubMed ID: 21472146
    [No Abstract]   [Full Text] [Related]  

  • 18. Teaching time for metered-dose inhalers in the emergency setting.
    Numata Y; Bourbeau J; Ernst P; Duquette G; Schwartzman K
    Chest; 2002 Aug; 122(2):498-504. PubMed ID: 12171822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-bronchodilator spirometry reference values in adults and implications for disease management.
    Johannessen A; Lehmann S; Omenaas ER; Eide GE; Bakke PS; Gulsvik A
    Am J Respir Crit Care Med; 2006 Jun; 173(12):1316-25. PubMed ID: 16556696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Salbutamol in Mixed Obstructive and Restrictive Pattern Spirometry.
    Tuladhar LR; Tamrakar Tuladhar ET
    Kathmandu Univ Med J (KUMJ); 2017 Oct.-Dec.; 15(60):279-283. PubMed ID: 30580341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.